1Boyle JJ.Macrophage activation in atherosclerosis:pathogenesis and pharmacology of plaque rapture[J].Curr Vasc Pharmacol,2005,3(1):63-68.
2Saam T,Hatsukami TS,Takaya N,et al.The vulnerable,or high-rlsk,atherosclerotic plaque:noninvasive MR imaging for characterization and assessment[J].Radiology,2007,244(1):64-77.
3Kinlay S,Egido J.Inflammatory biomarkers in stable atherosclerosis[J].Am J Cardiol,2006,98(11A):2-8.
4Packard RR,Libby P.Inflammation in atherosclerosis:from vascular biology to biomarker discovery and risk predictio[J].Clin Chem,2008,54(1):24-38.
5Ferri C,Croce G,Cofini V,et al.C-reactive protein:interaction with the vascular endothelium and possible role in human atherosclerosis[J].Curr Pharm Des,2007,13(16):1631-1645.
6Burke AP,Tracy RP,Kolodgie F,et al.Elevated Creactive protein values and atherosclerosis in sudden coronary death:association with different pathologies[J].Circulation,2002,105 (17):2019-2023.
7Koenig W,Khuseyinova N.Biomarkers of atherosclerotic plaque instability and rupture[J].Arterioscler Thromb Vase Biol,2007,27(1):15-26.
8Virani SS,Polsani VR,Nambi V.Novel markers of inflammation in atherosclerosis[J].Curr Atheroscler Rep,2008,10(2):164-170.
9Deo R,Khera A,McGuire DK,et al.Association among plasma levels of monocyte ehemoattractant protein-1,traditional cardiovascular risk factors,and subclinical atherosclerosis[J].J Am Coll Cardiol,2004,44 (9):1812-1818.
10Boekholdt SM,Keller TT,Wareham NJ,et al.Serum levels of type Ⅱ secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women:the EPIC-Norfolk Prospective Population Study[J].Arterioscler Thromb Vase Biol,2005,25(4):839-846.
6NAGHAVI M, LIBBY P, FALK E,et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies[J]. Cireulation , 2003 , 108: 1664-1672.
7LUND J, QIN Q P, ILVA T, et al. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin Ⅰ elevation[J]. Circulation, 2003,21, 108: 1924-1926.
8WU A H. The ischemia modified albumin biomarker for myocardial ischemia [J]. MLO Med Lab Obs,2003 , 35:36-38, 40.
9LAWRENCE J B, OXVIG C, OVERGAARD M T,et al. The insulin-like growth factor(IGF)-depcndent IGF protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A[J]. Proc Natl Acad Sci USA , 1999, 96:3149-3153.
10BAYES-GENIS A, CONOVER C A, OVERGAARDM T, et al. Pregnancy associated plasma protein A as a marker of acute coronary syndromes[J]. N Engl J Med, 2001, 345: 1022-1029.
6Saenger A K, Christenson R H. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment[J]. Clin Chem,2010,56:21-33.
7Chen S, Birk D E. Focus on molecules: decorin[J]. Exp Eye Res,2011,92:444-445.
8IozzoRV, Moscatello D K, McQuillan D J, Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor[J]. J Biol Chem, 1999,274 : 4489-4492.
9Sch6nherr E,Sunderk6tter C,Iozzo R V,Schaefer L. Decorin,a novel player in the insulin-like growth factor system[J].J Biol Chem,2005,280:15767-15772.
10Kresse H,Sch6nherr E. Proteoglycans of the extracellular ma- trix and growth control[J]. J Cell Physiol, 2001,189 : 266-274.
